Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621001544864
Ethics application status
Approved
Date submitted
30/09/2021
Date registered
12/11/2021
Date last updated
6/03/2023
Date data sharing statement initially provided
12/11/2021
Date results provided
14/10/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
An evaluation of an information linker service for families with a child diagnosed with genetic epilepsy.
Scientific title
A pre-post pilot evaluation of ‘GenE Compass’: Linking families and clinicians with the highest quality information about developmental and epileptic encephalopathies
Secondary ID [1] 305449 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Developmental and epileptic encephalopathy 323825 0
Condition category
Condition code
Neurological 321332 321332 0 0
Epilepsy
Human Genetics and Inherited Disorders 321333 321333 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
GenE Compass is a personalised information service for parents/caregivers (herein referred to as caregivers). Caregivers can submit questions on their child’s DEE to our ‘information linker’ via an online form or via phone call (the linker will verbally obtain information for the form on the call and submit on the caregivers’ behalf). They can do this either independently or in partnership with a healthcare professional. Caregivers will be able to ask as many questions as they link within their 3-months access to GenE Compass.

Questions can be about their child’s specific diagnosis such as about expected co-morbidities, natural history information, support resources, what current research is being conducted on that condition, how gene therapies or precision medicine works. In regards to clinical trials, we will not provide any recommendations of enrolment. Rather, we will provide links to support caregivers to access this information themselves. We will only provide specific treatment information for a genetic diagnosis if it is within international consensus guidelines.

We have consulted clinical, medicolegal and clinical ethics experts and have designed GenE Compass as an information resource which compliments but does not replace clinical care. Therefore we have made it clear that we cannot offer specific management advice (e.g. advice on choice of one therapy over another) for individual patient or families, as that is under the jurisdiction of the individual managing physicians. We have clearly managed expectations for the scope of GenE Compass in the recruitment information and have provided a pathway for highlighting what requests are ‘out of scope’ for the pilot

The GenE Compass information linker, is a professional person with expertise in collating medical information and explaining this to families, who will be responsible for:
1. triaging queries to Level A or B
2. researching the peer-reviewed literature to answer the caregivers’ questions
3. preparing an initial report and discussing their findings at the weekly GenE Compass multi-disciplinary team meeting (including clinical geneticists, genetic counsellors, a neurologist, and clinical nurse consultant).
4. finalising the report and sending it back to the caregiver and the caregivers’ nominated healthcare professionals.

Questions are triaged into Level A or B queries. Level A queries are defined as “Out of scope of GenE Compass, can be best responded to by a known alternative service/organisation, or simple response required OR consists of a clinical question which will need to be addressed by one of the child’s clinicians as greater context is required.” Should a query be considered Level A by the information linker and senior multidisciplinary team members (i.e. a epileptologist, and two clinical geneticists), the linker will email the caregiver directly providing information about why their question is outside of the scope of GenE Compass and recommendations for caregivers next step. For example, if a caregiver submits a question about increasing medication dose due to an increase in seizure frequency, the information linker will clarify that GenE Compass is not a medical service and will direct the caregiver to contact their child’s neurologist and/or paediatrician.

Level B queries are defined as “Questions related to information about a DEE or comorbidities, but not direct patient care” (i.e. within scope of GenE Compass). In these cases, the linker will conduct their rapid literature review, prepare an initial report, consult with the expert multidisciplinary team and finalise the report.

The report will be written at a maximum Grade 8 readability (Flesch-Kincaid readability score; with the primary readership being the caregivers). An important part of GenE Compass will be the assessment of the quality of web-resources, as we anticipate that some of the information that will be sought will not be in peer-reviewed articles. Building on our experience of running pennsw.org.au we will also pilot a star rating of information. For example, a '***' rating will indicate that information provided is supported by at least 1 article in a peer-reviewed journal for that particular cohort.

We anticipate that we will return a report to the caregiver within 10 business days, however we will be exploring the feasibility of the GenE Compass in this evaluation. We anticipate it will take 5-10 business days based on previous research done by Swinglehurst et al (2001) and our capacity to run weekly GenE Compass multi-disciplinary team meeting.

We anticipate that the report will be delivered in a standard format. However, we will be examining the queries that are sent to our service and iterating the report format and content so that it is most valuable to each family, yet sustainable long-term.

If necessary, the report will be shared with the caregivers with the support of Aboriginal liaison workers and/or Interpreter services.

At the end of our evaluation we will examine the quality of the information that shared within our reports. This will provide a list gaps in current evidence for future researchers and clinicians to explore.

Prior to sending out to a caregiver, all reports will be reviewed by at least two clinicians on our expert multidisciplinary team. For example, a query about genetic testing may require a clinical geneticist and genetic counsellor to approve the report, vs. a question about seizures and impact on mental health may require a epileptologist and psychiatrist to approve the report. This will ensure that while the information linker is responsible for the reports, the senior clinicians are accountable and hold ultimate ownership of information provided.

The information the linker obtains for commonly asked questions will also be uploaded onto www.pennsw.org.au. This means that the information gained through this pilot will also be available for caregivers globally. This generated information will also be advertised via our CoGENeS social media pages, GenE Compass study newsletter, CoGENeS family days, our collaborators, Genetic Epilepsy Team Australia (GETA) and Epilepsy Smart program to maximise knowledge dissemination.

Thus, the pilot will provide a ‘living information resource’, tailored to the most frequently asked questions of parents of children with genetic DEE, but available free of access to families and clinicians internationally.
Intervention code [1] 321841 0
Other interventions
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 329116 0
Caregivers' acceptability of GenE Compass We will assess caregivers’ acceptability in Questionnaire 2 (after 3-months of access to GenE Compass). We will assess caregivers’ acceptability through an adapted version of the Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is a validated measure that is used to assess satisfaction with a service. It has been commonly used to evaluate healthcare services. We will also assess acceptability through 2 purpose-designed open-ended items. Caregivers will have the opportunity to also participate in a semi-structured interview after they complete Questionnaire 2. This 30-minute, audio-recorded interview, will explore acceptability and potential benefit of GenE Compass, and areas for improvement.
Timepoint [1] 329116 0
3-months after access to GenE Compass. We had recruited 45 participants when this change had occured, none of which had completed their 3-months access of GenE Compass at that point.
Primary outcome [2] 329117 0
Feasibility of GenE Compass

We will examine feasibility by recruitment rates, retention rates, number of questions submitted (within scope and outside of scope), time taken to respond to caregivers, time required for multidisciplinary team meetings, calls vs. question forms submitted to GenE Compass, number of calls/emails and questions asked to the SCHN epilepsy consultant nurse specialists, and any distress caused by reports indicating in the feedback forms. This data will also be used to identify potential barriers and enablers to sucessful implementation.

We will collect the following from our study recruitment database and an audit of study records:
- recruitment rates
- retention rates
- time required for multidisciplinary team meetings in a separate database

We will collect the following through REDCap, entered by participants or our study team
- number of questions submitted (per participant and overall), within and outside of scope
- time taken to respond to caregivers
- calls and question forms submitted to GenE Compass
- any distress caused by reports (via the report-specific feedback forms)

The SCHN epilepsy nurse consultants log all phone/email communications on the electronic medical records. We will obtain the number of calls/emails and questions asked by GenE Compass families via the Health Information Services at SCHN.
Timepoint [2] 329117 0
3-months after access to GenE Compass.
Primary outcome [3] 329531 0
Clinicians' acceptability of GenE Compass

We will assess Compass clinicians’ acceptability through an adapted version of the CSQ-8, and 3 purpose-designed open-ended items.
Timepoint [3] 329531 0
We will assess clinicians’ acceptability at end of study.
Secondary outcome [1] 401519 0
Parental quality of life

We will be using the ASCOT Adult Social Care Outcomes Toolkit – four-level self-completion questionnaire (SCT4) for carers. The validated ASCOT-Carer SCT4 is a self-completion version of the Adult Social Care Outcomes Toolkit (ASCOT) designed to measure the social care-related quality of life (SCRQoL) of carers aged 18 years or over. ASCOT-Carer SCRQoL refers to those aspects of a carer’s quality of life that are relevant to, and the focus of, social care interventions.
Timepoint [1] 401519 0
3-months after access to GenE Compass
Secondary outcome [2] 401521 0
Information seeking behaviours

We will collect this information via three purpose-designed items: one open-ended response and two checkbox selections.
Timepoint [2] 401521 0
3-months after access to GenE Compass
Secondary outcome [3] 401522 0
Percieved view of their child's illness

We will assess this outcome via the Brief Illness Perceptions Questionnaire (Brief IPQ). The Brief IPQ is a validated measure of perceived view of the illness, with the final Question 9 regarding the causation of illness removed as it is not relevant to study aims and does not contribute to the overall Brief IPQ score. This measure as has previously been used to measure perceptions in parents who have a child with a neurological condition, and has also been shown to be sensitive to change.
Timepoint [3] 401522 0
3-months after access to GenE Compass
Secondary outcome [4] 401524 0
Patient activation

The measure we will use to assess this is the Patient Activation Measure – short form (PAM – short form). The PAM is a validated measure of patient knowledge, skill, and confidence for self-management, adapted for this study. Using this measure, better patient activation appears to be linked to better health outcomes and healthcare satisfaction, and improved self-management.
Timepoint [4] 401524 0
3-months after access to GenE Compass

Eligibility
Key inclusion criteria
Caregivers will be eligible if:
1.. They have a child (<18 years of age at time of study invitation) with a clinically suspected or confirmed diagnosis of a developmental and epileptic encephalopathy (e.g. SCN2A-encephalopathy, WWOX-encephalopathy). If a child transitions to the adult health system during the course of the study they will remain eligible for the remaining study period
2. Are a new or existing patients of the Sydney Children’s Hospitals Network.
3. Can read/speak English

Caregivers will be required to nominate their child's GP, Paediatrician and Neurologist. These clinicians will receive a copy of the caregivers' report. Clinicians who receive a report in the first 6-months of the study being open will be eligible to complete a questionnaire. Clinicians who receive a report in the second 6-months of the study being open will be eligible to complete another questionnaire (maximum two questionnaires for each clinician).
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Caregivers deemed, by one of their clinicians, as having significant acute mental health illness such as currently experiencing suicidal ideation or symptoms of psychosis. This is to mitigate further burden on the highly vulnerable families until we determine acceptability and safety of our intervention.

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Pre-post design
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
For this pilot evaluation, we plan to recruit at least ~88 caregivers, which will allow for an estimated final sample size of 53. This will allow us to answer our primary research questions, but also gain some insight into GenE Compass’ effectiveness in preparation for our randomised controlled trial (to be conducted should our pilot be successful). This sample size is also realistic as it takes into consideration anticipated attrition due to the longitudinal design.

Based on the expected number of participants, we anticipate at least 50 unique healthcare professionals will be nominated. Based on an estimated response rate in clinicians (i.e. 30%), we anticipate ~15 clinicians will complete our questionnaire at the 6-month mark, and ~15 clinicians will complete our questionnaire at the 12-month mark.

We will analyse all data using SPSS24 (IBM Corp, Armonk, NY). We will use descriptive statistics to describe demographics and assess acceptability. Parametric and non-parametric statistical analyses will be used as appropriate, to examine pre-post intervention differences (exact McNemar tests). We will also examine the role of health literacy level and remoteness on outcomes. p-Values < 0.05 will be considered statistically significant.

We will use NVivo (Version 12, QSR International) to conduct a directed qualitative content analysis of interview transcripts and any open-ended responses. Two authors will code all responses independently to ensure rigor, with any discordant coding discussed and revised.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
17/01/2022
Actual
9/02/2022
Date of last participant enrolment
Anticipated
20/05/2022
Actual
3/06/2022
Date of last data collection
Anticipated
8/11/2022
Actual
30/11/2022
Sample size
Target
88
Accrual to date
Final
72
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 20643 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 20644 0
The Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 35432 0
2031 - Randwick
Recruitment postcode(s) [2] 35433 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 309806 0
Charities/Societies/Foundations
Name [1] 309806 0
Manildra Group
Country [1] 309806 0
Australia
Primary sponsor type
University
Name
UNSW Sydney
Address
UNSW Sydney
High St
Kensington, NSW 2052
Country
Australia
Secondary sponsor category [1] 310838 0
None
Name [1] 310838 0
Address [1] 310838 0
Country [1] 310838 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 309553 0
Sydney Children's Hospitals Network HREC
Ethics committee address [1] 309553 0
Ethics committee country [1] 309553 0
Australia
Date submitted for ethics approval [1] 309553 0
19/08/2021
Approval date [1] 309553 0
22/09/2021
Ethics approval number [1] 309553 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 114566 0
Dr Elizabeth (Emma) Palmer
Address 114566 0
UNSW Sydney
Room 810, Level 8, Bright Alliance Building
NSW 2052
Country 114566 0
Australia
Phone 114566 0
+61 432101381
Fax 114566 0
Email 114566 0
elizabeth.palmer@unsw.edu.au
Contact person for public queries
Name 114567 0
Eden Robertson
Address 114567 0
UNSW Sydney
Level 8, Bright Alliance Building
NSW 2052
Country 114567 0
Australia
Phone 114567 0
+61 450 620 723
Fax 114567 0
Email 114567 0
eden.robertson@unsw.edu.au
Contact person for scientific queries
Name 114568 0
Eden Robertson
Address 114568 0
UNSW Sydney
Level 8, Bright Alliance Building
NSW 2052
Country 114568 0
Australia
Phone 114568 0
+61 450 620 723
Fax 114568 0
Email 114568 0
eden.robertson@unsw.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Given the rarity of DEE, there is potential that participants will be identifiable. Given the unique nature of our intervention, we will not share any study supporting documents. However, we intend to publish the protocol for this trial which will be freely available through an open access journal.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
18501Study protocolRobertson EG, Kelada L, Best S, et al. Acceptability and feasibility of an online information linker service for caregivers who have a child with genetic epilepsy: a mixed-method pilot study protocolBMJ Open 2022;12:e063249. doi: 10.1136/bmjopen-2022-063249https://bmjopen.bmj.com/content/12/10/e063249 



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseAcceptability and feasibility of an online information linker service for caregivers who have a child with genetic epilepsy: A mixed-method pilot study protocol.2022https://dx.doi.org/10.1136/bmjopen-2022-063249
Embase"Somewhere to turn to with my questions": A pre-post pilot of an information linker service for caregivers who have a child with a Developmental and Epileptic Encephalopathy.2023https://dx.doi.org/10.1016/j.ejpn.2023.09.010
EmbaseQuality of life in caregivers of a child with a developmental and epileptic encephalopathy.2024https://dx.doi.org/10.1111/dmcn.15695
N.B. These documents automatically identified may not have been verified by the study sponsor.